Company Filing History:
Years Active: 2013
Title: The Innovative Contributions of Robert R. Becklin
Introduction
Robert R. Becklin is a notable inventor based in Layton, UT (US). He has made significant contributions to the field of biomedical research, particularly in the development of antitumor agents. His work has implications for cancer treatment, showcasing the potential of innovative compounds in medical applications.
Latest Patents
Becklin holds a patent for "Quinoxaline derivatives as antitumor agents." This invention relates to methods of screening for binding partners that are essential for the biological activity of erastin, specifically targeting VDACs such as VDAC3. The patent also provides reagents and methods for effectively killing cancer cells using erastin and its related compounds or derivatives. He has 1 patent to his name, reflecting his focused contributions to cancer research.
Career Highlights
Throughout his career, Becklin has worked with prominent organizations in the biomedical field. He has been associated with Prolexys Pharmaceuticals, Inc., where he contributed to the development of innovative pharmaceutical solutions. Additionally, he has worked at the Whitehead Institute for Biomedical Research, further enhancing his expertise in biomedical research and innovation.
Collaborations
Becklin has collaborated with notable colleagues, including Cindy Lou Chepanoske and John M. Peltier. These collaborations have likely enriched his research and contributed to the advancement of his projects.
Conclusion
Robert R. Becklin's work exemplifies the impact of innovation in the field of cancer research. His patent on quinoxaline derivatives highlights the potential for new treatments in oncology. His career reflects a commitment to advancing medical science through innovative research and collaboration.